PMC:7267243 / 931-1776 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"63","span":{"begin":286,"end":294},"obj":"Species"},{"id":"64","span":{"begin":754,"end":762},"obj":"Species"},{"id":"65","span":{"begin":676,"end":685},"obj":"Species"},{"id":"66","span":{"begin":15,"end":44},"obj":"Disease"},{"id":"67","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"68","span":{"begin":187,"end":219},"obj":"Disease"},{"id":"69","span":{"begin":300,"end":335},"obj":"Disease"},{"id":"70","span":{"begin":337,"end":341},"obj":"Disease"},{"id":"71","span":{"begin":350,"end":365},"obj":"Disease"},{"id":"72","span":{"begin":408,"end":430},"obj":"Disease"},{"id":"73","span":{"begin":562,"end":571},"obj":"Disease"},{"id":"74","span":{"begin":582,"end":597},"obj":"Disease"},{"id":"75","span":{"begin":606,"end":610},"obj":"Disease"},{"id":"76","span":{"begin":615,"end":622},"obj":"Disease"},{"id":"77","span":{"begin":707,"end":720},"obj":"Disease"},{"id":"78","span":{"begin":768,"end":776},"obj":"Disease"},{"id":"79","span":{"begin":788,"end":792},"obj":"Disease"}],"attributes":[{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:9606"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"Tax:9606"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"Tax:11309"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:C000657245"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D055744"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"MESH:D012128"},{"id":"A70","pred":"tao:has_database_id","subj":"70","obj":"MESH:D012128"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"MESH:D001102"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:D055744"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:D010243"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:D001102"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D012128"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:D000860"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:D001228"},{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"MESH:C000657245"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T22","span":{"begin":20,"end":44},"obj":"Disease"},{"id":"T23","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"T24","span":{"begin":206,"end":219},"obj":"Disease"},{"id":"T25","span":{"begin":300,"end":335},"obj":"Disease"},{"id":"T26","span":{"begin":306,"end":335},"obj":"Disease"},{"id":"T27","span":{"begin":337,"end":341},"obj":"Disease"},{"id":"T28","span":{"begin":350,"end":365},"obj":"Disease"},{"id":"T29","span":{"begin":356,"end":365},"obj":"Disease"},{"id":"T30","span":{"begin":408,"end":430},"obj":"Disease"},{"id":"T31","span":{"begin":417,"end":430},"obj":"Disease"},{"id":"T32","span":{"begin":582,"end":597},"obj":"Disease"},{"id":"T33","span":{"begin":588,"end":597},"obj":"Disease"},{"id":"T34","span":{"begin":606,"end":610},"obj":"Disease"},{"id":"T35","span":{"begin":676,"end":685},"obj":"Disease"},{"id":"T36","span":{"begin":707,"end":720},"obj":"Disease"},{"id":"T37","span":{"begin":768,"end":776},"obj":"Disease"},{"id":"T38","span":{"begin":788,"end":792},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T4","span":{"begin":148,"end":149},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":504,"end":510},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T6","span":{"begin":829,"end":830},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":221,"end":224},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A2","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":350,"end":365},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T3","span":{"begin":582,"end":597},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":166},"obj":"Sentence"},{"id":"T16","span":{"begin":167,"end":276},"obj":"Sentence"},{"id":"T17","span":{"begin":277,"end":498},"obj":"Sentence"},{"id":"T18","span":{"begin":499,"end":660},"obj":"Sentence"},{"id":"T19","span":{"begin":661,"end":845},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":187,"end":219},"obj":"Phenotype"},{"id":"T5","span":{"begin":221,"end":224},"obj":"Phenotype"},{"id":"T6","span":{"begin":306,"end":326},"obj":"Phenotype"},{"id":"T7","span":{"begin":562,"end":571},"obj":"Phenotype"},{"id":"T8","span":{"begin":615,"end":622},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0003470"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0012418"}],"text":"Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre."}